# 2026-16442: Researchers Offer Antibodies Targeting a Viral Clue in Liver Cancer

2026-16442, Government Owned Invention Available for License: Human Antibodies Targeting Beneficial Viral Peptide in Liver Cancer, is a Federal Register notice from Health and Human Services Department, National Institutes of Health published 2026-08-12; PRIA reads it as touching household money (as of 2026-10-28).

- Canonical: https://policyrisk.com/federal-register/2026-16442
- As of: 2026-10-28
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-16442
- Title: Government Owned Invention Available for License: Human Antibodies Targeting Beneficial Viral Peptide in Liver Cancer
- Type: Notice
- Agencies: Health and Human Services Department; National Institutes of Health
- Citation: 91 FR 52060
- Published: 2026-08-12
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-28

## In one line

Researchers Offer Antibodies Targeting a Viral Clue in Liver Cancer

## Summary

The National Cancer Institute has created special human antibodies that target a unique viral peptide linked to liver cancer. These antibodies could help treat liver cancer more effectively, especially for patients who don’t respond well to current therapies. Researchers and companies interested in developing these treatments can now license this invention and start working on it.

## Abstract

The National Cancer Institute (NCI) seeks research co- development partners and/or licensees to develop a collection of anti- CE1 antibodies for liver cancer treatment.

## Effects PRIA read

- NCI Offering License for Anti-CE1 Antibodies: benefit, medium. The National Cancer Institute (NCI) is offering a license/co-development opportunity for a collection of human anti-CE1 antibodies (NIH Reference Number: E-021-2025) intended for liver cancer treatment. The technology is at the pre-clinical stage (in vivo validation) and a provisional patent was fi…
- Potential New Treatment for Liver Cancer: benefit, high. NCI-developed human anti-CE1 antibodies (B9 and B10) specifically bind liver cancer cells and inhibited hepatocellular carcinoma (HCC) tumor growth via natural killer cell-mediated antibody-dependent cellular cytotoxicity in vitro and in vivo. The antibodies are described as having potential to be…
- Preclinical Model and Screening Tool Available: benefit, low. The notice identifies a companion preclinical model using the MC38 colon cancer system (including B2m knockout versus wild-type comparisons) that uniquely models checkpoint-resistance mechanisms and is described as regulatorily de-risked (Related Technology NIH Ref: E-023-2024). NCI lists this mode…

## Related documents

- [2026-21816](https://policyrisk.com/federal-register/2026-21816): Center for Scientific Review; Notice of Closed Meetings, 2026-10-26
- [2026-21689](https://policyrisk.com/federal-register/2026-21689): Center for Scientific Review; Notice of Closed Meetings, 2026-10-23
- [2026-21688](https://policyrisk.com/federal-register/2026-21688): Center for Scientific Review; Notice of Closed Meetings, 2026-10-23
- [2026-21527](https://policyrisk.com/federal-register/2026-21527): Center for Scientific Review; Notice of Closed Meetings, 2026-10-21
- [2026-21526](https://policyrisk.com/federal-register/2026-21526): Center for Scientific Review; Notice of Closed Meetings, 2026-10-21
- [2026-21525](https://policyrisk.com/federal-register/2026-21525): Center for Scientific Review; Notice of Closed Meetings, 2026-10-21

## Sources
- [2026-16442 on federalregister.gov](https://www.federalregister.gov/documents/2026/08/12/2026-16442/government-owned-invention-available-for-license-human-antibodies-targeting-beneficial-viral-peptide)
- [2026-16442 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16442.pdf)

## Related
- [Previous: 2026-16441, Government Owned Invention Available for License: DNA Methylation-Based Cancer…](https://policyrisk.com/federal-register/2026-16441)
- [Next: 2026-16443, Government Owned Invention Available for License: Monoclonal Antibody (RO4) Tha…](https://policyrisk.com/federal-register/2026-16443)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-16442 (as of 2026-10-28).